4.00
+0.39(+10.80%)
Currency In USD
| Previous Close | 3.61 |
| Open | 3.72 |
| Day High | 4.26 |
| Day Low | 3.58 |
| 52-Week High | 11.46 |
| 52-Week Low | 1.07 |
| Volume | 5.46M |
| Average Volume | 2.11M |
| Market Cap | 385.17M |
| PE | -4.94 |
| EPS | -0.81 |
| Moving Average 50 Days | 3.27 |
| Moving Average 200 Days | 5.37 |
| Change | 0.39 |
Rezolute to Participate in the Citizens Life Sciences Conference
GlobeNewswire Inc.
Mar 04, 2026 12:00 PM GMT
REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced th
Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
GlobeNewswire Inc.
Feb 12, 2026 9:05 PM GMT
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported fina
Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 04, 2026 12:00 PM GMT
REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced tha